Press Releases Detail:
AVITAR, INC. presents at Forensic Sciences & Crime Technology Conference (FRENZY).
May 09, 2000
CANTON, MA, May 9, 2000–Avitar, Inc. (AMEX:AVR) announced today that Dr. Carl M. Good III, Vice President of Research and Development, will be a featured speaker at the Forensic Sciences & Crime Scene Technology Conference & Exposition (FRENZY), in Washington, DC, May 12, 2000. Dr. Good will deliver his presentation, "Oral Fluid Point-of-Contact Drugs of Abuse Test," during the session "Advances in Drug Detection Technology," being held at 10:00 AM. FRENZY is the first cross-disciplinary event to unite users of forensic and crime scene technologies.
"In addition to providing products to the marketplace, Avitar also wants to be a primary source for educational information on workplace drug abuse to the business community," said Peter Phildius, Chairman and Chief Executive Officer of Avitar. "Education is paramount to understanding drug abuse and the consequences of drugs in the work environment. Supplying technical information through our corporate website and expert speakers at various conferences will help companies solve their drug testing needs."
Carl M. Good, III, Ph.D. has more than 15 years experience in developing diagnostic tests since completing his doctorate in biochemical genetics at Iowa State University. Since joining Avitar, Inc. in 1997, as Vice President of Research and Development, Dr. Good has lead the development of non-invasive rapid screening diagnostic drugs of abuse tests. Dr. Good believes Avitar’s technologies offer valuable diagnostic tools for settings such as correctional facilities and the workplace.
Dr. Good will present Avitar’s product, ORALscreen™ 4 (TCOM) and its performance characteristics to the FRENZY conference. He will discuss the advantages of oral fluid testing for drugs of abuse with an on-site product over urine collection, focusing on the procedure for oral fluid testing for key drugs of abuse and performance data.
His data has been obtained from in-house studies as well as field trials in real use, including situations from methadone clinics and probation sites. In general, results are similar to urine testing for the first few days after drug use. Detecting marijuana in oral fluid is most useful as an indicator of being "under the influence" because of its unique ability to be detected immediately or within hours of use.
ORALscreen is the world’s first oral fluid point-of-contact drugs of abuse testing system. Avitar’s simple, reliable and portable drug test creates new investigative opportunities by allowing earlier, less invasive collection of toxicological evidence of marijuana (THC), cocaine, opiates, and methamphetamine.
FRENZY, Forensic Sciences & Crime Scene Technology Conference & Exposition, is a unique cross-disciplinary conference to unite users of forensic and crime scene technologies. A multi-tracked, four-day program will include panels, general sessions, workshops and networking sessions led by key associations, agencies and publications. Attendees will be able to select from a multi-tracked program with topics including: "Government Programs for Labs and Law Enforcement."
Avitar, Inc. (AMEX:AVR) headquartered in Canton, Massachusetts, develops, manufactures and markets innovative medical devices based on core technologies in oral fluid diagnostics and customized polyurethane applications. The Company markets a unique portfolio of substance abuse testing products and services that include ORALscreenTM, the world’s first rapid point-of-contact oral fluid test for drugs of abuse, HAIRscreenTM, a laboratory-based test for long term drug abuse using hair, and several other specialized tests for drugs of abuse. Avitar also markets an oral fluid collection system for DNA testing as well as a proprietary line of polyurethane-based high tech medical devices. For more information, see Avitar’s website at avitarinc.com .
This release contains forward looking statements that are subject to risks and uncertainties, including the development and marketing of new applications and other risks that are detailed from time to time in the Company’s filings with the Securities and Exchange Commission.